Personalized immunonutrition for patients with obesity should be the first therapeutic choice to reduce the risk of infections and the disease course in COVID-19 patients. That therapeutic strategy could be effective in case of other potential epidemic infections. It would also allow a reduction of the enormous medical care cost supported by the National Health Service.